Presentation by The College of Pharmacists of British Columbia and The BC Centre for Disease Control on the distribution of Naloxone in community Pharmacy practice.
Pharmacological Classification, Mechanism of Action, Clinical Uses, Administration Routes, Dosing for Adults and Pediatrics, Pharmacokinetics, Dose Adjustments, Patient Counseling, Adverse Effects, Drug Interactions, Contraindications, Personal Experience with Ondansetron, Future Clinical Uses of Ondansetron
Some of the factors that increase the risk of overdose are: Injecting rather than smoking drug, mixing drugs (especially heroin, benzos, alcohol, methadone, etc. which are respiratory depressants), using alone, the variable purity of street drugs, using in unfamiliar surroundings, using with unfamiliar people increase the risks of overdose. Some of the risky times are those in which we have lost tolerance, we are at the beginning / ending substitute medication and we are in difficult life events.
Some of the external signs of overdose is a person unconscious, that cannot be woken, cyanosis (blue tinge to lips, tip of nose, eye bags, finger tips or nails), not breathing at all or taking slow/shallow or infrequent breaths and pin point pupils.
Pharmacological Classification, Mechanism of Action, Clinical Uses, Administration Routes, Dosing for Adults and Pediatrics, Pharmacokinetics, Dose Adjustments, Patient Counseling, Adverse Effects, Drug Interactions, Contraindications, Personal Experience with Ondansetron, Future Clinical Uses of Ondansetron
Some of the factors that increase the risk of overdose are: Injecting rather than smoking drug, mixing drugs (especially heroin, benzos, alcohol, methadone, etc. which are respiratory depressants), using alone, the variable purity of street drugs, using in unfamiliar surroundings, using with unfamiliar people increase the risks of overdose. Some of the risky times are those in which we have lost tolerance, we are at the beginning / ending substitute medication and we are in difficult life events.
Some of the external signs of overdose is a person unconscious, that cannot be woken, cyanosis (blue tinge to lips, tip of nose, eye bags, finger tips or nails), not breathing at all or taking slow/shallow or infrequent breaths and pin point pupils.
Anticholinsterases are chemicals that prevent the breakdown of the
neurotransmitter acetylcholine or butyrylcholine.
• This increases the amount of the acetylcholine or butyrylcholine in the
synaptic cleft that can bind to muscarinic receptors, nicotinic receptors
and others.
THIS ppt explains in brief about general anesthesia for under graduates. It includes brief classification, mechanism of action, side effects of some important drugs. concepts like diffusion hypoxia, second gas effect, balanced anesthesia and pre- anaesthetic medication are discussed.
general anesthesia are the drug given before surgery which have reversible effect on consciousness. discussing ideal GA, stages of GA, mechanism of action of GA, classification of drugs parenteral or inhaled.
Ondansetron
Class
• Seratonin ( 5-HT3) antagonist.
Uses
1. The management of nausea and vomiting induced by chemotherapy and
radiotherapy .
2. In the prevention and treatment of PONV
Main action
• Antiemetic.
Anticholinsterases are chemicals that prevent the breakdown of the
neurotransmitter acetylcholine or butyrylcholine.
• This increases the amount of the acetylcholine or butyrylcholine in the
synaptic cleft that can bind to muscarinic receptors, nicotinic receptors
and others.
THIS ppt explains in brief about general anesthesia for under graduates. It includes brief classification, mechanism of action, side effects of some important drugs. concepts like diffusion hypoxia, second gas effect, balanced anesthesia and pre- anaesthetic medication are discussed.
general anesthesia are the drug given before surgery which have reversible effect on consciousness. discussing ideal GA, stages of GA, mechanism of action of GA, classification of drugs parenteral or inhaled.
Ondansetron
Class
• Seratonin ( 5-HT3) antagonist.
Uses
1. The management of nausea and vomiting induced by chemotherapy and
radiotherapy .
2. In the prevention and treatment of PONV
Main action
• Antiemetic.
Opioid overdose has emerged as one of the leading causes of preventable death in the United States. Paramedics and emergency department staff know that naloxone is the best treatment for opioid overdose and have been using this antidote for over 40 years. In the past few years, programs distributing naloxone are being implemented by EMT-Basics, firefighters, law enforcement first responders and members of the community. Dr. Dailey served as the medical director for a New York State pilot project for the implementation of BLS naloxone, has trained law enforcement providers in several states and routinely prescribes naloxone to members of the community.
Every year in the US over 320,000 people (of all ages) die from Sudden Cardiac Arrest (SCA) outside of hospitals. While Fire and EMS departments do a great job trying to save these people time is not on their side. Severe brain damage occurs withing 4-6 minutes and brain death by 10 minutes.
On scene bystanders are the best chance for these victims. Prompt CPR and early use of an AED will dramatically increase the victims chance of survival. This presentation is a brief overview on how to use an Automated External Defibrillator (AED). This presentation should not take away from that fact that all people need to attend a formal CPR and AED course.
First Response Training, LLC is a West Palm Beach CPR training facility owned by Conor Devery who has over 20 years of pre hospital and critical care medical experience. First Response Training, LLC provides training for the medical and non medical communities in South Florida. Courses taught include CPR, AED, BLS, First Aid, ACLS, PALS, and EKG. For further information please contact Conor at (561) 459-0221 or vissit him at www.gotcpr.us
Preventing Opioid Overdose Deaths with Take-home Naloxone/ NIHB PolicyPASaskatchewan
An overview of Take Home Naloxone including who should be counselled, some counselling tips and most importantly how to recognize and respond to an opioid overdose using Naloxone. We will finish off the discussion with Non-Insured Health Benefits (NIHB) coverage and where to go when you have questions or difficulties in obtaining drug coverage for your patients.
Latest advice released advising on dosing regime with Naloxone. Dosing is very important for a number of reasons, in suggested dose of 4.0mgs then three minutes later if no response a further 4.0mg/ml, reduces the onset of withdrawals of the person being brought round. Also reduces risk of adverse effects should there be any underlying health issues that may react negatively.
Rob mentions chest compression's only at 21 minutes?? Short sound bite https://youtu.be/1RDPzZ_XPwo Suggest everyone read the pharmacist Bible the 'CPS' Found here https://www.linkedin.com/pulse/college-pharmacists-june-7-2016-gary-thompson
Self evident all the signs of overdose could be any respiratory emergency and proves the heart is beating and dying lack of oxygen, rescue breaths ASAP
Bill Matthews from the Harm Reduction Coalition presents an overview of opiate overdose prevention. Presented at the Harm Reduction Coalition's 8th National Conference, November 18-21, 2010 in Austin, Texas.
the presentation talks about the insecticides used in public health and its impact on human health. Ways of insecticide exposure to human health and clinical manifestations due to insecticide exposure.
In 2016, the Centers for Disease Control and Prevention (CDC)
introduced guidelines for prescribing opioids to chronic pain
patients. These guidelines apply to physicians treating patients
outside the context of cancer, palliative, and end-of-life care. The
goal of the guidelines was to reduce the number of people who
misuse or abuse opioids, while still ensuring that patients have
access to safe and effective treatment for chronic pain.
Administration of drug through nasal route is referred as Nasal drug delivery system.
Nasal administration is a route of administration in which the drug are insufflated through the nose for either local or systematic effect.
Nasal route is an alternative to invasive administrations and provides a direct access to the systemic circulation.
Penetration Enhancers:
Mechanism:
Inhibit enzymatic activity
Reduce mucus viscosity
Reduce MCC
Open tight junctions
Solubilize the drug
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
India Diagnostic Labs Market: Dynamics, Key Players, and Industry Projections...Kumar Satyam
According to the TechSci Research report titled “India Diagnostic Labs Market Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2019-2029,” the India Diagnostic Labs Market was valued at USD 16,471.21 million in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 11.55% through 2029. This significant growth can be attributed to various factors, including collaborations and partnerships among leading companies, the expansion of diagnostic chains, and increasing accessibility to diagnostic services across the country. This comprehensive report delves into the market dynamics, recent trends, drivers, competitive landscape, and benefits of the research report, providing a detailed analysis of the India Diagnostic Labs Market.
Collaborations and Partnerships
Collaborations and partnerships among leading companies play a pivotal role in driving the growth of the India Diagnostic Labs Market. These strategic alliances allow companies to merge their expertise, strengthen their market positions, and offer innovative solutions. By combining resources, companies can enhance their research and development capabilities, expand their product portfolios, and improve their distribution networks. These collaborations also facilitate the sharing of technological advancements and best practices, contributing to the overall growth of the market.
Expansion of Diagnostic Chains
The expansion of diagnostic chains is a driving force behind the growing demand for diagnostic lab services. Diagnostic chains often establish multiple laboratories and diagnostic centers in various cities and regions, including urban and rural areas. This expanded network makes diagnostic services more accessible to a larger portion of the population, addressing healthcare disparities and reaching underserved populations. The presence of diagnostic chain facilities in multiple locations within a city or region provides convenience for patients, reducing travel time and effort. A broader network of labs often leads to reduced waiting times for appointments and sample collection, ensuring that patients receive timely and efficient diagnostic services.
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a significant driver for the demand for diagnostic lab services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require regular monitoring and diagnostic testing for effective management. The rise in chronic diseases necessitates the use of advanced diagnostic tools and technologies, driving the growth of the diagnostic labs market. Additionally, early diagnosis and timely intervention are crucial for managing chronic diseases, further boosting the demand for diagnostic lab services.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Naloxone Training Presentation
1. Community Pharmacy Distribution of Naloxone
College of Pharmacists of BC
BC Centre for Disease Control – Harm Reduction Program
Sponsored in part by the BC Ministry of Health
Presented as part of the Naloxone Education Session at the Sheraton Vancouver Guildford
Hotel in Surrey BC on April 5, 2016.
2. Update - December 14, 2016
At the time of publication, Naloxone was still classified as a Schedule II drug, and this presentation
reflects this. However, in September of 2016, The College of Pharmacists of BC changed the status of
Naloxone to ‘unscheduled,’ making it available anywhere to anyone.
BC was the first province in Canada to make non-prescription naloxone available outside of
pharmacies.
4. • it cannot be abused
• no effect in absence of opioids
• simply restores breathing
• used in Canada for 40+ years
• does not increase risk taking
Naloxone is Safe
5. WHO Guidelines, November 2014
http://apps.who.int/iris/bitstream/10665/137462/1/9789241548816_eng.pdf?ua=1&ua=1
World Health Organization Recommendation
6. Take Home Naloxone programs combine overdose recognition and
response training (including administration of naloxone) with provision of
‘take home naloxone kits’
Training is for lay people are trained, and kits are intended to be used in
the community on peers or by friends or family members
The BCCDC Take Home Naloxone Program has been in operation since
August of 2012.
Since then, over 6500 lay people have been trained and over 450
overdoses have been reversed
Evidence supporting lay people giving naloxone
7. Prescription opioid-related
deaths in BC (2004-2013):
• Women: 558
• Men: 1116
Smolina et al. 2015.
Fatal overdoses in both illicit and
licit opioid users often involve:
• Polypharmacy
• Comorbidities
Why is Naloxone Needed?
Opioid overdoses are a serious public health issue
8. Illicit drug overdose
deaths are increasing
across the province
BC Coroners Service, 2015
Why is Naloxone Needed?
9. Over ¾ of overdoses are witnessed by someone
• Overwhelming evidence that with appropriate training, lay people
can recognize and respond to opioid overdoses, including giving an
intramuscular injection of naloxone.
• Timely restoration of normal breathing reduces deaths and harms
like severe brain damage.
• While ambulance (and firefighters in some communities) have
access to naloxone, long wait-times mean that without naloxone
lay responders must do rescue breathing for extended periods of
time
Why is Naloxone Needed?
10. • Provide patient education and training
• Provide naloxone and suggest supplies
Remember
Naloxone is a Schedule II drug to ensure pharmacists provide
education and not to prevent access
Increasing Accessibility Through Pharmacies
11. NEW! Pharmacy distribution of naloxone
Target:
General public
Family & friends of people using opioids
Ongoing: BCCDC Take Home Naloxone
Target:
Marginalized populations
First Nations communities
Special Public Health Program
Implications for BC
12. High dose opioid prescription (>100mg/day morphine equivalence)
Entering/tapering methadone maintenance treatment
Opioid (illicit and Rx) use by people:
• with breathing problems (respiratory illness/obstruction)
• with kidney and/or liver disease
• also using depressants e.g. alcohol and benzos/sleeping tabs
• also taking some anti-depressants
People who use illicit opioids
Reduced tolerance due to abstinence (prison, detox)
Difficulty accessing emergency services (remote/rural areas)
Populations That Benefit From Naloxone
13. • People who want to be able to recognize and respond to
opioid overdose
• Family & friends of people who use prescription or illicit
opioids
Who Else Might Ask for Naloxone?
14. Medication Prep and Check Area
Drop-off Counter Pick-up Counter
Respect Patient’s Right to Privacy
19. Suggested Dosing
Naloxone Hydrochloride: 0.4mg/ml, 1 ml [vial /amp]
Suggested dose to be sold: 2 doses (i.e. 2 ml of 0.4 mg/ml)
Omega Labs
DIN # 02393034
Sandoz Canada
DIN # 02148706
DIN # 02382601
(preservative free)
Alveda Pharma
DIN #02382482
20. Remember: Only injectable naloxone available
Need 1 needle per ampoule/vial
Recommended: safety syringes
• 3 ml
• 25G x 1” needle
Suggested Supplies: Needles
22. • Breathing mask
• Gloves
• Alcohol swabs
• Training supplies (water
ampoules or vials)
Additional Suggested Supplies
23. Rational for Schedule II is injectable format not safety concerns
No limits on:
• Age of purchaser
• Quantity to be purchased
• Frequency of purchase
Reminder: Pharmacists are NOT a Gatekeeper
24. Where to purchase?
• Contact wholesalers or manufacturers (NOT BCCDC)
How much do I purchase?
• Ask around for interest in new service
Naloxone dating at time of sale?
• At least 6 months
• Ideally >1 year
Purchasing
26. Recordkeeping:
• Refer to Health Professionals Act – Bylaws
• Requirements are the same for any Schedule II drug
Storage and Disposal Guidelines:
• See product monograph
Other Guidelines
27. Training materials for pharmacists and patients
• www.bcpharmacists.org/naloxone
CPBC Practice Support
• practicesupport@bcpharmacists.org
• 604-733-2440
• 1-800-663-1940
BC Drug and Poison Information Centre
• 1-800-567-9811
Questions?